Hepatocellular Carcinoma Hcc clinical trials

Explore recruiting hepatocellular carcinoma hcc clinical trials.

Recruiting hepatocellular carcinoma hcc studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Hepatocellular Carcinoma Hcc trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A prospective, randomized, placebo-controlled, double-blind, multicenter phase III registration clinical study to compare toripalimab (JS001) combined with lenvatinib versus placebo combined with lenvatinib as the 1st-line therapy for advanced hepatocellular carcinoma (HCC)

Poland, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Registry Study of Treatment With Bulevirtide in Participants With Chronic Hepatitis D Infection

France, Austria, Germany, Romania, Belgium, Spain +1 more

Therapeutic use (Phase IV) EU CTIS Study details

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Atezolizumab and Bevacizumab, with and without Tiragolumab, In Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma

Belgium, France, Italy, Germany, Spain, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

A first-in-human study to learn about the safety of BAY 3547926 and how well it works in participants with advanced liver cancer

Spain, Belgium, Finland, France

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Multiple Solid Tumors

Netherlands, France, Belgium, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB WITH LENVATINIB OR SORAFENIB VERSUS SORAFENIB OR LENVATINIB ALONE IN HEPATOCELLULAR CARCINOMA PREVIOUSLY TREATED WITH ATEZOLIZUMAB AND BEVACIZUMAB

Finland, Spain, Belgium, France, Austria, Greece +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Hepatocellular Carcinoma Hcc trials by city

Hepatocellular Carcinoma Hcc in Toronto Hepatocellular Carcinoma Hcc in Vancouver Hepatocellular Carcinoma Hcc in Montreal Hepatocellular Carcinoma Hcc in Calgary Hepatocellular Carcinoma Hcc in Edmonton Hepatocellular Carcinoma Hcc in Ottawa Hepatocellular Carcinoma Hcc in Winnipeg Hepatocellular Carcinoma Hcc in Quebec City Hepatocellular Carcinoma Hcc in Hamilton Hepatocellular Carcinoma Hcc in Kitchener Hepatocellular Carcinoma Hcc in London Hepatocellular Carcinoma Hcc in Halifax Hepatocellular Carcinoma Hcc in New York Hepatocellular Carcinoma Hcc in Los Angeles Hepatocellular Carcinoma Hcc in Chicago Hepatocellular Carcinoma Hcc in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease